


CLAIMS

1. A pharmaceutically acceptable salt of a compound of formula (Ia):



(Ia),

wherein the pharmaceutically acceptable salt is a citric acid (citrate) salt; or a methanesulfonic acid (mesylate) salt; ~~a saccharin (saccharinate) salt or an oxalic acid (oxalate) salt.~~

2. A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one citric acid (citrate) salt (E1).
3. The crystalline form of claim 2, having an XRPD pattern with peaks at 2θ values $15.2\pm0.2^\circ$, $23.7\pm0.2^\circ$ and $24.8\pm0.2^\circ$.
4. The crystalline form of claim 2, having an XRPD pattern with peaks at 2θ values $12.0\pm0.2^\circ$, $15.2\pm0.2^\circ$, $15.7\pm0.2^\circ$, $21.7\pm0.2^\circ$, $23.7\pm0.2^\circ$ and $24.8\pm0.2^\circ$.
5. The crystalline form of claim 2, having an XRPD pattern substantially as shown in FIG. 1.
6. A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one methanesulfonic acid (mesylate) salt (E2).

7. The crystalline form of claim 6, having an XRPD pattern with peaks at 2θ values $17.9\pm0.2^\circ$, $24.5\pm0.2^\circ$ and $26.3\pm0.2^\circ$.

8. The crystalline form of claim 6, having an XRPD pattern with peaks at 2θ values $15.8\pm0.2^\circ$, $17.9\pm0.2^\circ$, $19.1\pm0.2^\circ$, $24.5\pm0.2^\circ$, $25.1\pm0.2^\circ$ and $26.3\pm0.2^\circ$.

9. The crystalline form of claim 6, having an XRPD pattern substantially as shown in FIG. 3.

~~10. — A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one saccharin (saccharinate) salt (E5).~~

~~11. — The crystalline form of claim 10, having 2θ values $6.4\pm0.2^\circ$, $12.8\pm0.2^\circ$ and $15.4\pm0.2^\circ$.~~

~~12. — The crystalline form of claim 10, having 2θ values $6.4\pm0.2^\circ$, $7.7\pm0.2^\circ$, $12.8\pm0.2^\circ$, $15.4\pm0.2^\circ$, $19.8\pm0.2^\circ$ and $26.3\pm0.2^\circ$.~~

~~13. — The crystalline form of claim 10, having an XRPD pattern substantially as shown in FIG. 7.~~

~~14. — A crystalline form of the pharmaceutically acceptable salt of claim 1, wherein the pharmaceutically acceptable salt is (2R,5S)-7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one oxalic acid (oxalate) salt (E6).~~

~~15. — The crystalline form of claim 14, having an XRPD pattern with peaks at 2θ values $7.9\pm0.2^\circ$, $16.0\pm0.2^\circ$ and $16.7\pm0.2^\circ$.~~

~~16. — The crystalline form of claim 14, having an XRPD pattern with peaks at 2θ values $7.9\pm0.2^\circ$, $14.8\pm0.2^\circ$, $16.0\pm0.2^\circ$, $16.7\pm0.2^\circ$, $17.8\pm0.2^\circ$, $24.3\pm0.2^\circ$ and $26.4\pm0.2^\circ$.~~

~~17. The crystalline form of claim 14, having an XRPD pattern substantially as shown in FIG. 8.~~

~~18. A crystalline form of (2R,5S)-7 Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one (E4), having an XRPD pattern with peaks at 2 θ values 4.1 $\pm$ 0.2 $^{\circ}$, 17.0 $\pm$ 0.2 $^{\circ}$, and 22.5 $\pm$ 0.2 $^{\circ}$.~~

~~19. The crystalline form of claim 18, having an XRPD pattern with peaks at 2 θ values 4.1 $\pm$ 0.2 $^{\circ}$, 12.5 $\pm$ 0.2 $^{\circ}$, 14.9 $\pm$ 0.2 $^{\circ}$, 17.0 $\pm$ 0.2 $^{\circ}$, 20.8 $\pm$ 0.2 $^{\circ}$ and 22.5 $\pm$ 0.2 $^{\circ}$.~~

~~20. The crystalline form of claim 19, having an XRPD pattern substantially as shown in FIG. 6.~~

~~21~~ 10. A pharmaceutical composition comprising the pharmaceutically acceptable salt of claim 1 or the crystalline form of claims ~~2-17~~ 2-9, and one or more pharmaceutically acceptable carrier(s), diluents(s) and/or excipient(s).

~~22~~ 11. The pharmaceutically acceptable salt of claim 1 or the crystalline form of claims ~~2-21~~ 2-9 for use in the treatment of a disease or condition mediated by modulation of voltage-gated sodium channels.